INTRODUCTION
Psoriasis is a chronic immune mediated disease of inflammatory dermatosis that affects 3.2% of adults in the United States and leads to a significant reduction in quality of life.1 The most common type of psoriasis is plaque psoriasis, which is characterized in moderate to severe disease by well-demarcated erythematous scaly plaques. Psoriasis pathogenesis involves the abnormal regulation of the cells of the immune system (white blood cells including T lymphocytes, neutrophils, and other leucocytes) prompted by both environmental and genetic factors, which leads to a dysregulation of normal keratinocyte proliferation and an increase in proinflammatory cell signals.4,5
Although there is no cure for psoriasis, medical treatments can control existing disease and reduce the associated signs and symptoms. Topical formulations are the most widely used treatment option for localized plaques.2,3,6 Historically, topical corticosteroids have been the most commonly used drugs for the treatment of psoriasis and other refractory dermatoses because of their marked anti-inflammatory, antiproliferative, antipruritic, and immunomodulatory activities.7
Halobetasol propionate (HBP) is a super-potent Class I topical corticosteroid for the treatment of dermal diseases with a history of over 25 years of clinical use. HBP (chemically known as 21- chloro-6α, 9-difluoro-11β,17-dihydroxy-16β-methylpregna-1, 4-diene-3, 20-dione 17- propionate) is a trihalogenated molecule, which increases its anti-inflammatory and antiproliferative
Although there is no cure for psoriasis, medical treatments can control existing disease and reduce the associated signs and symptoms. Topical formulations are the most widely used treatment option for localized plaques.2,3,6 Historically, topical corticosteroids have been the most commonly used drugs for the treatment of psoriasis and other refractory dermatoses because of their marked anti-inflammatory, antiproliferative, antipruritic, and immunomodulatory activities.7
Halobetasol propionate (HBP) is a super-potent Class I topical corticosteroid for the treatment of dermal diseases with a history of over 25 years of clinical use. HBP (chemically known as 21- chloro-6α, 9-difluoro-11β,17-dihydroxy-16β-methylpregna-1, 4-diene-3, 20-dione 17- propionate) is a trihalogenated molecule, which increases its anti-inflammatory and antiproliferative